6838 台新藥每月營收
| 年度/月份 | 營業收入 (單位:千元) | 累計營業收入 (單位:千元) |
|---|
| 單月營收 | 去年同月營收 | 單月月增率 | 單月年增率 | 累計營收 | 去年累計營收 | 累積年增率 |
|---|
| 2025/07 | 0 | 0 | - | - | 5,358 | 133,128 | -95.98% |
| 2025/06 | 0 | 4,757 | -100.00% | -100.00% | 5,358 | 133,128 | -95.98% |
| 2025/05 | 4,764 | 571 | - | 734.33% | 5,358 | 128,371 | -95.83% |
| 2025/04 | 0 | 0 | - | - | 594 | 127,800 | -99.54% |
| 2025/03 | 0 | 127,800 | -100.00% | -100.00% | 594 | 127,800 | -99.54% |
| 2025/02 | 594 | 0 | - | - | 594 | 0 | - |
| 2025/01 | 0 | 0 | - | - | 0 | 0 | - |
| 2024/12 | 0 | 0 | -100.00% | - | 143,356 | 31,172 | 359.89% |
| 2024/11 | 2,407 | 0 | -30.99% | - | 143,356 | 31,172 | 359.89% |
| 2024/10 | 3,488 | 0 | -19.50% | - | 140,949 | 31,172 | 352.17% |
| 2024/09 | 4,333 | 573 | - | 656.20% | 137,461 | 31,172 | 340.98% |
| 2024/08 | 0 | 0 | - | - | 133,128 | 30,599 | 335.07% |
| 2024/07 | 0 | 0 | -100.00% | - | 133,128 | 30,599 | 335.07% |
| 2024/06 | 4,757 | 30,599 | 733.10% | -84.45% | 133,128 | 30,599 | 335.07% |
| 2024/05 | 571 | 0 | - | - | 128,371 | 0 | - |
| 2024/04 | 0 | 0 | -100.00% | - | 127,800 | 0 | - |
| 2024/03 | 127,800 | 0 | - | - | 127,800 | 0 | - |
| 2024/02 | 0 | 0 | - | - | 0 | 0 | - |
| 2024/01 | 0 | 0 | - | - | 0 | 0 | - |
| 2023/12 | 0 | 0 | - | - | 31,172 | 1,315 | 2270.49% |
| 2023/11 | 0 | 0 | - | - | 31,172 | 1,315 | 2270.49% |
| 2023/10 | 0 | 0 | -100.00% | - | 31,172 | 1,315 | 2270.49% |
| 2023/09 | 573 | 533 | - | 7.50% | 31,172 | 1,315 | 2270.49% |
| 2023/08 | 0 | 446 | - | -100.00% | 30,599 | 782 | 3812.92% |
| 2023/07 | 0 | 0 | -100.00% | - | 30,599 | 336 | 9006.85% |
| 2023/06 | 30,599 | 0 | - | - | 30,599 | 336 | 9006.85% |
| 2023/05 | 0 | 0 | - | - | 0 | 336 | -100.00% |
| 2023/04 | 0 | 336 | - | -100.00% | 0 | 336 | -100.00% |
| 2023/03 | 0 | 0 | - | - | 0 | 0 | - |
| 2023/02 | 0 | 0 | - | - | 0 | 0 | - |
| 2023/01 | 0 | 0 | - | - | 0 | 0 | - |
| 2022/12 | 0 | 0 | - | - | 1,315 | 28,529 | -95.39% |
| 2022/11 | 0 | 0 | - | - | 1,315 | 28,529 | -95.39% |
| 2022/10 | 0 | 0 | -100.00% | - | 1,315 | 28,529 | -95.39% |
| 2022/09 | 533 | 295 | 19.51% | 80.68% | 1,315 | 28,529 | -95.39% |
| 2022/08 | 446 | 0 | - | - | 782 | 28,234 | -97.23% |
| 2022/07 | 0 | 0 | - | - | 336 | 28,234 | -98.81% |
| 2022/06 | 0 | 27,851 | - | -100.00% | 336 | 28,234 | -98.81% |
| 2022/05 | 0 | 0 | -100.00% | - | 336 | 383 | -12.27% |
| 2022/04 | 336 | 0 | - | - | 336 | 383 | -12.27% |
| 2022/03 | 0 | 383 | - | -100.00% | 0 | 383 | -100.00% |
| 2022/02 | 0 | 0 | - | - | 0 | 0 | - |
| 2022/01 | 0 | 0 | - | - | 0 | 0 | - |
| 2021/12 | 0 | 0 | - | - | 28,529 | 0 | - |
| 2021/11 | 0 | 0 | - | - | 28,529 | 0 | - |
| 2021/10 | 0 | 0 | -100.00% | - | 28,529 | 0 | - |
| 2021/09 | 295 | 0 | - | - | 28,529 | 0 | - |
| 2021/08 | 0 | 0 | - | - | 28,234 | 0 | - |
| 2021/07 | 0 | 0 | -100.00% | - | 28,234 | 0 | - |
| 2021/06 | 27,851 | 0 | - | - | 28,234 | 0 | - |
| 2021/05 | 0 | 0 | - | - | 383 | 0 | - |